ALK Lung Cancer Patient Shares Hope: Targeted Therapy Enables Grandchild Witnessing
SingTao · 1 SOURCESabout 2 hours ago6 MIN
Summary
A 60-year-old Hong Kong woman diagnosed with ALK-positive lung cancer has shared her journey of reclaiming her life through targeted therapy. After her cancer recurred in 2024, she began treatment with a third-generation ALK inhibitor, which has allowed her to witness her grandchild's birth and actively participate in family life. A new survey by the Cancer Information Net Charitable Foundation reveals that while 80% of non-small cell lung cancer patients prioritize extending life in their treatment decisions, financial burdens remain a significant barrier, with 63% of ALK-positive patients spending over HK$10,000 monthly on medication. The findings highlight the urgent need for government drug subsidies to ensure patients can access life-changing treatments locally.
Key Points
- Ms. Chung (鍾女士), 60, an ALK-positive lung cancer patient, experienced cancer recurrence in 2024 and started third-generation ALK inhibitor therapy, regaining the ability to witness her grandchild's birth and care for family .
- The Cancer Information Net Charitable Foundation survey of 104 patients found 80% rank prolonging life among their top three treatment considerations, rising to 90% for ALK-positive patients .
- Financial strain is severe: 63% of ALK-positive patients pay over HK$10,000 monthly out-of-pocket, while 42% of all respondents live in households earning below HK$20,000 per month .
- Half of surveyed patients have sought medication in mainland China, with some delaying scans, reducing dosages, or discontinuing treatment entirely due to costs .
- Nearly 90% of patients would remain in Hong Kong for treatment if government subsidies were provided, demonstrating strong preference for local care .
- Clinical oncologist Dr. Lu Wing-sim explains third-generation ALK inhibitors now show median progression-free survival exceeding 84 months, compared to approximately 10 months with first-generation drugs .
Why It Matters
This patient's story challenges the perception of advanced lung cancer as a death sentence, demonstrating how targeted therapy can transform it into a manageable chronic condition. The survey findings underscore that without government intervention, financial barriers may force Hong Kong patients to seek cheaper alternatives elsewhere, potentially compromising care quality and continuity. As precision oncology advances, ensuring equitable access to life-extending treatments becomes a critical healthcare policy imperative for Hong Kong .
This patient's story challenges the perception of advanced lung cancer as a death sentence, demonstrating how targeted therapy can transform it into a manageable chronic condition. The survey findings underscore that without government intervention, financial barriers may force Hong Kong patients to seek cheaper alternatives elsewhere, potentially compromising care quality and continuity. As precision oncology advances, ensuring equitable access to life-extending treatments becomes a critical healthcare policy imperative for Hong Kong .